Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

92,226 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.
Guan Z, Xu B, DeSilvio ML, Shen Z, Arpornwirat W, Tong Z, Lorvidhaya V, Jiang Z, Yang J, Makhson A, Leung WL, Russo MW, Newstat B, Wang L, Chen G, Oliva C, Gomez H. Guan Z, et al. Among authors: yang j. J Clin Oncol. 2013 Jun 1;31(16):1947-53. doi: 10.1200/JCO.2011.40.5241. Epub 2013 Mar 18. J Clin Oncol. 2013. PMID: 23509322 Clinical Trial.
Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial.
Xu B, Jiang Z, Shao Z, Wang J, Feng J, Song S, Chen Z, Gu K, Yu S, Zhang Y, Wang C, Zhang F, Yang J. Xu B, et al. Among authors: yang j. Cancer Chemother Pharmacol. 2011 Jan;67(1):223-30. doi: 10.1007/s00280-010-1483-x. Epub 2010 Oct 12. Cancer Chemother Pharmacol. 2011. PMID: 20938664 Clinical Trial.
Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone.
Xu B, Guan Z, Shen Z, Tong Z, Jiang Z, Yang J, DeSilvio M, Russo M, Leigh M, Ellis C. Xu B, et al. Among authors: yang j. Breast Cancer Res. 2014 Jul 24;16(4):405. doi: 10.1186/s13058-014-0405-y. Breast Cancer Res. 2014. PMID: 25056500 Free PMC article.
Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial.
Zhang P, Sun T, Zhang Q, Yuan Z, Jiang Z, Wang XJ, Cui S, Teng Y, Hu XC, Yang J, Pan H, Tong Z, Li H, Yao Q, Wang Y, Yin Y, Sun P, Zheng H, Cheng J, Lu J, Zhang B, Geng C, Liu J, Peng R, Yan M, Zhang S, Huang J, Tang L, Qiu R, Xu B; BG01-1323L study group. Zhang P, et al. Among authors: yang j. Lancet Oncol. 2017 Mar;18(3):371-383. doi: 10.1016/S1470-2045(17)30088-8. Epub 2017 Feb 11. Lancet Oncol. 2017. PMID: 28209298 Clinical Trial.
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group. Martin M, et al. Lancet Oncol. 2017 Dec;18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9. Epub 2017 Nov 13. Lancet Oncol. 2017. PMID: 29146401 Clinical Trial.
Chinese expert consensus on the clinical diagnosis and treatment of advanced breast cancer (2018).
Xu B, Hu X, Feng J, Geng C, Jin F, Li H, Li M, Li Q, Liao N, Liu D, Liu J, Liu Q, Lu J, Liu Z, Ma F, Ouyang Q, Pan Y, Shen K, Sun T, Teng Y, Tong Z, Wang B, Wang H, Wang S, Wang S, Wang T, Wang X, Wang X, Wang Y, Wang Z, Wu J, Yan M, Yang J, Yin Y, Yuan P, Zhang J, Zhang P, Zhang Q, Zheng H. Xu B, et al. Among authors: yang j. Cancer. 2020 Aug 15;126 Suppl 16:3867-3882. doi: 10.1002/cncr.32832. Cancer. 2020. PMID: 32710660 Free article.
A prospective, open-label, multicenter phase IV clinical trial on the safety and efficacy of lobaplatin-based chemotherapy in advanced breast cancer.
Yan M, Yuan P, Ouyang Q, Cheng Y, Han G, Wang D, Ran L, Sun T, Zhao D, Bai Y, Yang S, Wang X, Wu R, Zeng X, Yao H, Ji X, Jiang J, Hu X, Lin H, Zheng L, Zhu Z, Ge W, Yang J, Cui T, Zhang X, Lu F, Li W, Xu H, Kang M, Gong P, Zou L, Liu J, Zhang H, Yu H, Xu B. Yan M, et al. Among authors: yang s, yang j. Ther Adv Med Oncol. 2022 Oct 24;14:17588359221122715. doi: 10.1177/17588359221122715. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 36330235 Free PMC article.
Efficacy and safety of inetetamab in combination with chemotherapy as first-line treatment of HER2-positive metastatic breast cancer: a subgroup analysis in the HOPES study.
Wang T, Zhang P, Di L, Wang X, Yang J, Tong Z, Liu J, Feng J, Liu D, Yu Q, Liu Y, Yu H, Jiang Z. Wang T, et al. Among authors: yang j. Transl Breast Cancer Res. 2022 Apr 30;3:15. doi: 10.21037/tbcr-21-42. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751509 Free PMC article.
92,226 results
You have reached the last available page of results. Please see the User Guide for more information.